Luzi L, Hering B J, Socci C, Raptis G, Battezzati A, Terruzzi I, Falqui L, Brandhorst H, Brandhorst D, Regalia E, Brambilla E, Secchi A, Perseghin G, Maffi P, Bianchi E, Mazzaferro V, Gennari L, Di Carlo V, Federlin K, Pozza G, Bretzel R G
Department of Internal Medicine, San Raphael Scientific Institute, University of Milan, Milan, Italy.
J Clin Invest. 1996 Jun 1;97(11):2611-8. doi: 10.1172/JCI118710.
The intraportal injection of human pancreatic islets has been indicated as a possible alternative to the pancreas transplant in insulin-dependent diabetic patients. Aim of the present work was to study the effect of intraportal injection of purified human islets on: (a) the basal hepatic glucose production; (b) the whole body glucose homeostasis and insulin action; and (c) the regulation of insulin secretion in insulin-dependent diabetes mellitus patients bearing a kidney transplant. 15 recipients of purified islets from cadaver donors (intraportal injection) were studied by means of the infusion of labeled glucose to quantify the hepatic glucose production. Islet transplanted patients were subdivided in two groups based on graft function and underwent: (a) a 120-min euglycemic insulin infusion (1 mU/kg/min) to assess insulin action; (b) a 120-min glucose infusion (+75 mg/di) to study the pattern of insulin secretion. Seven patients with chronic uveitis on the same immunosuppressive therapy as grafted patients, twelve healthy volunteers, and seven insulin-dependent diabetic patients with combined pancreas and kidney transplantation were also studied as control groups. Islet transplanted patients have: (a) a higher basal hepatic glucose production (HGP: 5.1 +/- 1.4 mg/kg/ min; P < 0.05 with respect to all other groups) if without graft function, and a normal HGP (2.4 +/- 0.2 mg/kg/min) with a functioning graft; (b) a defective tissue glucose disposal (3.9 +/- 0.5 mg/kg/min in patients without islet function and 5.3 +/- 0.4 mg/kg/min in patients with islet function) with respect to normals (P < 0.01 for both comparisons); (c) a blunted first phase insulin peak and a similar second phase secretion with respect to controls. In conclusion, in spite of the persistence of an abnormal pattern of insulin secretion, successful intraportal islet graft normalizes the basal HGP and improves total tissue glucose disposal in insulin-dependent diabetes mellitus.
门静脉内注射人胰岛已被认为是胰岛素依赖型糖尿病患者胰腺移植的一种可能替代方法。本研究的目的是探讨门静脉内注射纯化人胰岛对以下方面的影响:(a)基础肝葡萄糖生成;(b)全身葡萄糖稳态和胰岛素作用;(c)肾移植的胰岛素依赖型糖尿病患者胰岛素分泌的调节。通过输注标记葡萄糖来定量肝葡萄糖生成,对15例接受尸体供体纯化胰岛(门静脉内注射)的受者进行了研究。胰岛移植患者根据移植物功能分为两组,并接受:(a)120分钟的正常血糖胰岛素输注(1 mU/kg/分钟)以评估胰岛素作用;(b)120分钟的葡萄糖输注(+75 mg/di)以研究胰岛素分泌模式。还研究了7例接受与移植患者相同免疫抑制治疗的慢性葡萄膜炎患者、12名健康志愿者以及7例胰腺和肾脏联合移植的胰岛素依赖型糖尿病患者作为对照组。胰岛移植患者有:(a)如果没有移植物功能,基础肝葡萄糖生成较高(HGP:5.1±1.4 mg/kg/分钟;与所有其他组相比,P<0.05),而有功能移植物时HGP正常(2.4±0.2 mg/kg/分钟);(b)与正常人相比,组织葡萄糖处置存在缺陷(无胰岛功能患者为3.9±0.5 mg/kg/分钟,有胰岛功能患者为5.3±0.4 mg/kg/分钟)(两项比较P均<0.01);(c)与对照组相比,胰岛素第一相峰值钝化,第二相分泌相似。总之,尽管胰岛素分泌模式仍异常,但成功的门静脉内胰岛移植可使基础HGP正常化,并改善胰岛素依赖型糖尿病患者的总组织葡萄糖处置。